Biogen Stock News

Another factual information on the "Global Neurocognitive Disorder Treatment Market" has as of late added by CMI to its storehouse. This global research report offers an inside and out examination of various perspectives, for example, global market patterns, pieces of

Analysts expect Biogen Inc. (NASDAQ:BIIB) to announce $2.63 billion in sales for the current fiscal quarter, according to Zacks Investment Research. Twenty Nine analysts have provided estimates for Biogens earnings, with estimates ranging from $2.54 billion to $2.78 billion. Biogen reported sales of $2.85 billion during the same quarter last year, which indicates a negative []

Viatris Inc. announced that the United States Court of Appeals for the Federal Circuit affirmed the June 2020 decision by the U.S. District Court for the Northern District of West Virginia invalidating Biogens Tecfidera® patent, U.S. Patent No. 8,399,514, for lack of written description. The company launched the first therapeutically []

Related Stocks: PFE , ROKU , PLUG , ZM , MRNA , APPS , BB , AMC , LMT , A , ABNB , AI , BIIB , NKLA , DAL , CMG , FSLY , DISCA ,

The firm also reduced a number of holdings in the 3rd quarter Check out Ronald Muhlenkamp Stock Picks » Download GuruFolio Report of Ronald Muhlenkamp (Updated on 12/13/2021) Related Stocks: EQC , BIIB , NVTA , CCJ , MTZ , BMY , BRK.B , MSFT , CVS , SLB ,

DUBLIN--(BUSINESS WIRE)--The "North America Biosimilars Market 2020-2030 by Product Type, Indication, Manufacturing, End User, and Country: Trend Forecast and Growth Opportunity" report has been added to ResearchAndMarkets.com''s offering. North America biosimilars market is expected to grow by 25.1% annually in the forecast period and reach $27.57 billion by 2030 driven by the affordability of biosimilar-based treatment, rising incidence of chronic diseases due to aging populations, patent expi

Muhlenkamp & Co. Inc., the investment firm founded by Ronald Muhlenkamp (Trades, Portfolio), released its portfolio for the third quarter earlier this month.

Collaboration aims to develop innovative machine learning and artificial intelligence solutions for personalized and earlier treatment in neurologyBiogen to gain exclusive rights to TheraPanacea te…

CAMBRIDGE, Mass. and PARIS, Dec. 14, 2021 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and TheraPanacea today announced that they have entered into a collaboration focused on multiple therapeutic areas in neuroscience, to further build on the companies’ existing relationship. The aim is to leverage machine learning (ML) and artificial intelligence (AI) analysis to develop digital health solutions that may improve patient care, accelerate drug development, and further the understanding of the underlying pathologies of neurological diseases.

Oregon will ask the Biden administration if its Medicaid program can avoid paying for drugs, like Biogen’s Alzheimer’s drug, Aduhelm, that were approved via the FDA’s fast-track pathway.

ARS Wealth Advisors Group LLC acquired a new stake in Biogen Inc. (NASDAQ:BIIB) during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 1,909 shares of the biotechnology companys stock, valued at approximately $540,000. Several other hedge funds and other institutional investors also recently bought []

DUBLIN--(BUSINESS WIRE)--The "Multiple Sclerosis Drugs Global Market Report 2021: COVID-19 Growth and Change to 2030" report has been added to ResearchAndMarkets.com''s offering. The global multiple sclerosis drugs market is expected to grow from $21.27 billion in 2020 to $22.04 billion in 2021 at a compound annual growth rate (CAGR) of 3.6%. The market is expected to reach $25.95 billion in 2025 at a CAGR of 4%. Major players in the multiple sclerosis drugs market are Biogen, Novartis, Roche, B

Boston Trust Walden Corp acquired a new position in Biogen Inc. (NASDAQ:BIIB) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 714 shares of the biotechnology company’s stock, valued at approximately $202,000. Other institutional investors and hedge funds have also […]

Investors hope the combination of laggards will make one go-getter Related Stocks: ABBV , AMGN , BIIB , NSE:BIOCON , MRK , NVS , PFE , RHHBY , VTRS , SNY ,